Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OMVE>>>>>>Profile / Contact Info
Omni Ventures, Inc.
7500 College Blvd.
5th Floor
Overland Park, Kansas 66210
Phone: 913-693-8073
Fax #: 913-693-8001
Website: http://www.omve.net
Website: http://www.omniventures.org
Email: support@omve.net
Pivo Associates
212-924-3548
SuperC. I have emptied the iBox & resigned the Whup Whup Hut. Sticking to "A Dawgg" & STOCK BADDIES. I dropped from 22 boards down to 10. Mike.
PWSV.02 920k vs 81k_vol10dayavg only up 5%, excellent signage... http://stockcharts.com/c-sc/sc?s=PWSV&p=D&yr=0&mn=3&dy=0&i=t40819010287&r=5136
sc
PERL - like the low float on this one.
Share Structure
Market Value1 $12,166,642 a/o Nov 07, 2011
Shares Outstanding 450,616,368 a/o Jun 30, 2011
Float 19,747,514 a/o Jun 30, 2011
Authorized Shares 450,616,368 a/o Jun 27, 2011
Par Value
ChartsPattersAndTrends. DragonflyPicks. DoogsDugout. ROYE.
http://investorshub.advfn.com/boards/board.aspx?board_id=10118
http://investorshub.advfn.com/boards/board.aspx?board_id=5966
http://investorshub.advfn.com/boards/board.aspx?board_id=11292
Howdy CA$H MONEY PLAYER$,
ROYE .011 is a fully reporting (OTCQB) stock with great share structure and PPS for entry with potential for nice bounce on news of royalty stake in oil and gas...
Share Structure
Market Value1 $943,401 a/o Nov 07, 2011
Shares Outstanding 85,763,731 a/o Jun 30, 2011
Float 41,000,000 a/o Mar 15, 2011
Authorized Shares 100,000,000 a/o Dec 02, 2007
ROYE NEWS:Royal Energy Bolstered by Encouraging News Regarding Its 4 Percent Overriding Royalty Interest in Natrona County, Wyoming Oil & Gas Lease
Industry Publication Reports Dallas-Based, Hunt Oil Has Spud the Horizontal Niobrara Within the Wind River Basin in Natrona County
BROOKLYN, NY, Nov 08, 2011 (MARKETWIRE via COMTEX) -- There is some encouraging news for Royal Energy Resources, Inc. (OTCBB: ROYE). According to a recent article in the Rocky Mountain Oil Journal, Dallas-based Hunt Oil, has spud the horizontal Niobrara within the Wind River Basin in Natrona County, Wyoming.
Royal owns a 4 percent royalty interest in an oil and gas lease in Natrona County. The overriding royalty interest encompasses over 300 mineral acres.
The article indicated that Hunt has moved in, rigged up and spud the Hoc#152896 NS, SE-SR G 31N 82 in Natrona County.
"This is very encouraging news for our royalty rights in Natrona County," stated Jacob Roth, President of Royal Energy Resources. "This validates the potential for our oil and gas production and future revenue. We are cautiously optimistic of achieving early success with this royalty interest."
Roth indicated that the company continues to aggressively pursue additional oil and gas mineral rights acquisitions.
About Royal Energy Resources, Inc.
Royal Energy Resources, Inc. ("Royal" or the "Company"), is an oil and gas exploration development stage exploration and production company and currently owns interests in other counties in Wyoming. Royal has developed a corporate strategy of identification, acquisition and development of domestic oil and gas reserves, thereby reducing U.S. dependence on foreign oil.
Safe Harbor Statement
Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties, and actual results could differ from those discussed. This material is for informational purposes only and is not an offer or solicitation to buy or sell the securities.
Contact:
Royal Energy Resources, Inc.
Jacob Roth
Ph: (800) 620-3029
SOURCE: Royal Energy Resources, Inc.
MamasHomemadePennyPlaysWithSideOfBiscuits. MOMO'sBREAKOUT BOARD.
TREASURE HUNTERS. MFTH.
http://investorshub.advfn.com/boards/board.aspx?board_id=22287
http://investorshub.advfn.com/boards/board.aspx?board_id=4929
http://investorshub.advfn.com/boards/board.aspx?board_id=19994
MFTH(0.02)$$HIGH BOUNCE ALERT$$ (MUST READ DD)>>>
MFTH has the world's FIRST US patented technology to eliminate administration of incorrect medicinal substances by hypodermic needle.
THIS MEANS NO MORE ACCIDENTAL DEATH DUE TO MISTAKES OF GIVING PATIENTS THE WRONG INJECTION.
MFTH's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching
between the substance and its intended patient.
What's unique is that MFTH's protector device has a locking mechanism that ensures substance is only released from the hypodermic needle after positive technology-based pre-matching is used with the specific patient, using barcode technology.
Using a barcode reader, the device confirms that the medication and dosage contained within a syringe are correctly intended for a medical patient. Upon electronic confirmation, the syringe locking-device opens, allowing for the administration of the syringe's contents.
THE DIRECT ANNUAL COST OF PREVENTABLE DRUG RELATED MORTALITY &
MORBIDITY $177.4 BILLION!!!
The global syringe market is estimated at $5.6 billion annually!
MFTH believes the market for their product could exceed $1 billion per year!
WATCH THE VIDEO ON THEIR WEBSITE >>>>
http://www.medisafe1.com/
MFTH just announced that they pre-paid two convertible promissory notes aggregating $57,000, including the interest due. The notes beared interest at 8% per annum and were due in August, 2011 and in October, 2011. The notes had conversion rights allowing the holder of the note at any time to convert all or any part of the remaining principal balance into MFTH`s common stock at a price equal to 58% of the average of the lowest three trading prices for the Common Stock during the most recent ten-day period.
http://ih.advfn.com/p.php?pid=nmona&article=49818230
MFTH began trading about a year ago at approximately $0.40 and then fell all the way down to below $0.01. MFTH has been starting to bounce big the past couple of days after their news that they paid back the two convertible promissory notes. These notes would have caused huge dilution to MFTH shareholders, which I believe is one of the main reasons MFTH fell so much and is trading so cheaply today.
watch for a BIG PRICE BOUNCE $$$$$$$and more NEWS
Pro Traders Forum. ABEW.
http://investorshub.advfn.com/boards/board.aspx?board_id=18631
ABEW.002 334kvs50k_vol10dayavg http://ih.advfn.com/p.php?pid=historical&cb=1264248899&symbol=abew
Interesting tech, check out comments/links on the board.
http://investorshub.advfn.com/boards/board.aspx?board_id=2425
Shell/Tech 'watch'
http://stockcharts.com/c-sc/sc?s=ABEW&p=D&yr=0&mn=2&dy=0&i=t57678436316&r=1762
http://www.thefreelibrary.com/Airbee+Wireless+and+Nanotron+Technologies+Announce+Partnership.-a0154424847
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58911317
This could of been IP ahead of it's time
Keep a CLOSE <0> on this one, now at 52wkhi for the year I think.
Shares Outstanding 124,070,140 a/o Jul 28, 2008
Float 15,547,426 a/o Feb 16, 2006
Accumulation since 11/03
We $$$ We
SuperC
MICRO Insider. COCO. SQNM.
http://investorshub.advfn.com/boards/board.aspx?board_id=17034
COCO--Insider purchased 100k shares at $2.54. Stock closed at $2.66. Everybody knows I was a big COCO homer over the past year or so, so I am not purchasing stock on this play because I have a lot of options on it, but I believe it will be an easy 8%'er. Do your own research.
insider data provided by www.scumfish.com
Corinthian Colleges, Inc. (Corinthian) is a post-secondary education company in the United States and Canada, serving the segment of the population seeking to acquire career-oriented education. As of June 30, 2010, the Company had a student enrollment of 110,580 and operated 101 schools in 25 states, and 17 schools in the province of Ontario, Canada. As of August 13, 2010 all of its schools operated under one of three national brands, Everest, WyoTech, or Heald. As of June 30, 2010, 101 out of 118 schools were operating under the Everest brand, six schools were operating under the WyoTech brand, and 11 schools were operating under the Heald brand. The Company offers a variety of diploma programs and associate's, bachelors and master's degrees through a single operating segment. Its training program areas include healthcare, criminal justice, mechanical, trades, business and information technology. On January 4, 2010, the Company completed its acquisition of Heald Capital, LLC.
.................................................................
SQNM--VP purchased 20k shares at $4.24. Stock closed at $4.24. Do your own research, but nice volume / share structure.
insider data provided by www.scumfish.com
Sequenom, Inc. (Sequenom) is a diagnostic testing and genetics analysis company. The Company is focused on providing products, services, diagnostic testing, applications and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock and other areas of research. Its development and commercialization efforts in various diagnostic areas include non-invasive women's health-related and prenatal diagnostics, ophthalmology, oncology, infectious diseases, and other medical conditions, disorders and diseases. The Company has two segments: Molecular Diagnostics and Genetic Analysis.
sorry..im a follower not a leader..
Who wants to take over as moderator of Clearing House Whup Whup Hut??
i hope we both fix that
Uh, I been so busy I forgot to make a lot of money....;-( Going to fix that.
well..goodmorning too u too..and everyone else..lets make some money today
Good Morning Clearing House.
Stock Legends. USPR. Then ATTD On BillChippasShow Tuesday:
http://investorshub.advfn.com/boards/board.aspx?board_id=20989
Watch The Bill Chippas Show Tuesday November 08, 2011 at 10:05 AM ET
We have a Great Show planned for Tuesday Nov 8th, 2011 Featuring OAttitude Drinks\271 ( ATTD) CEO Roy Warren and OUS Precious Metals\271 (USPR)Director John Gildae
Watch Live at 10:05 AM ET on WPSLTV.com (http://www.wpsltv.com)
Call in your questions to 772-340-1590 or Email questions to bill@billchippasshow.com
Listen Live from 10:05 AM ET till 11:00 AM ET at http://www.billchippasshow.com
Attitude Drinks is a beverage ( http://www.attitudedrinks.com) brand development and marketing company with a focus on delivering experiential, functional and healthful beverages. Today, (Nov 07, 2011) 'Attitude Drinks' announced a marketing endorsement partnership agreement with Professional Basketball Superstar Mr. Paul Pierce and his "Foundation for a Cause" a/k/a the Truth Fund charity. According to the agreement, Mr. Pierce and his "Foundation for a Cause" marketing endorsement will promote Attitude Drink's Phase III Recovery Drink. The term of the agreement is twelve months. See press release .
.................................................................
US Precious Metals Inc. http://www.uspmgold.com an exploration stage company engaged in the acquisition, exploration and development of mineral resource properties.
The Company focuses on gold and base mineral resource properties primarily located in the southern portion of the state of Micho\341can , Mexico.
US Precious Metals owns exploration and exploitation rights to approximately 37,000 acres of land. Since the demand of precious metals continues to rise, USPR is dedicated to survey, drill and sample on proven and probable reserves. U.S. Precious Metals Solidaridad Project has significant copper, gold, and silver resources. In 2002, USPR discovered The La Sabila property that is rich in mineral resources and became the hot spot for drilling. The estimated value of potential gold reserves was approximately $500 million based on 2008 mineral prices. At the current market price of gold , between $1500 and $1700 per troy ounce the present value would be over $512,000,000. An evaluation of their properties in 2010 also revealed 720,000 tons of copper. In July the Company partnered with DME Securities, LLC investment firm, a New York based bank & broker-dealer . DME will provide USPR with investment banking and financial advice for developing a strategy for company growth and success. DME plans to help USPR go forward with the Company\271s business plan and drilling campaigns, maximizing its\271 full potential by providing their financial expertise. DME is a member of the NYSE that provides the services of a licensed broker-dealer to multi-million dollar publically traded companies.
See the Princeton Research August 2011 Report on USPR.
An Audio Podcast will be available for Download after the Show at http://www.billchippasshow.com
Happy trading !
Bill Chippas, Host of OThe Bill Chippas Show\271
http://www.billchippasshow.com 1-772-236-9294
Twitter @billchippasshow Bill Chippas Show on Facebook Bill\271s Blog
STOCKGOODIES PLAYS OF THE WEEK. HIMR. For TUESDAY.
http://investorshub.advfn.com/boards/board.aspx?board_id=18582
Hollund Industrial Marine, Inc. HIMR
Business Description
Hollund Industrial Marine, Inc (Pink Sheets: HIMR) has developed an innovative heavy machine solution for the underwater forest industry called TigerLynk (www.TigerLynk.com). TigerLynk is a patented and proven machine technology that uses an industrial robot arm mounted on a vessel or platform to remotely cut and retrieve timber from underwater sources (lakes, reservoirs and rivers). Our Vice president, Dr. Claus Wagner-Bartak, leads Hollund?s team responsible for commercializing TigerLynk for the global marketplace. Dr. Bartak is an award-winning scientist who coordinated the research and development of the robot arm used on the NASA Space Shuttle (Canadarm 1).
Hollund has the exclusive patents to
TigerLynk Technology. TigerLynk is an innovative Underwater Remote Manipulator System designed for underwater logging and other challenging marine applications.
Tiger-Lynk is comprised of a vessel-mounted robotic manipulator which can provide a wide array of services in extreme murky, muddy and other limited vision conditions at underwater depths of up to 180 feet.
The Company is focused on the marketing and commercialization of the Tiger-Lynk Technology for underwater logging and construction, flood emergency services and underwater disaster response and offshore drilling markets.
John Haylock, President of the Company has been featured in an in-depth video interview on CEOinsiderTV.com.
The entire video is available to watch for free at http://ceoinsidertv.com/?hollund-industrial-marine
Mr. Haylock has over 40 years of business experience, providing accounting and auditing services to public companies, including mining, oil and gas. He has provided a wide range of administrative services to public companies for the past 6 years, and has a track record of successfully turning around underperforming companies. "I believe that Hollund has an historic opportunity to lead the forest sector toward a greener, more sustainable future. Leveraging Tigerlynk technology, I believe my experience will help Hollund reach its goal of becoming a global leader in underwater forestry and other marine sectors," states Mr. Haylock.
HIMR Security Details
Share Structure
Market Value1 $22,172,128 a/o Nov 04, 2011
Shares Outstanding 482,002,772 a/o Aug 25, 2011
Float 39,301,211 a/o Aug 25, 2011
Authorized Shares 10 Billion a/o Sept.21, 2011
Par Value 0.000001
Shareholders
Shareholders of Record 153 a/o Feb 01, 2011
Corporate Actions
Ex. Date Record Date Pay Date
Security Notes
* New & Secondary Issue=5-85 700,000 shs at $11 by Piper, Jaffray & Hopwood, Inc
* Capital Change=10-85 shs increased by 5 for 4 split
* Latest Addt'l & Secondary Issue=10-85 1,200,000 shs at $10.875 by Drexel Burnham Lambert, Inc et al.
* Capital Change=shs decreased by 1 for 100 split. Pay date=5-14-07
* Capital Change=shs increased by 17 for 1 split. Payable upon surrnder. Ex-date=11/20/2007. Rec date=11/20/2007. Pay date=11/20/2007.
* Capital Change=shs decreased by 1 for 100 split Pay date=06/25/2010.
* Capital Change=shs decreased by 1 for 1000 split. Pay date=01/19/2011.
Contact Info
* 107-417-477 Peace Portal Drive
* Blaine, WA 98230
* Website: http://www.hollundindustrial.com
* Phone: 604-534-8102
* Email: info@hollundindustrial.com
Stock goodies does not hold any shares in HIMR or has been compensated for this distributed email.
PoemStone. Sugo. Buy!
MOMO'S BREAKOUT BOARD. BLSP. DD.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68718782
BLSP .105x.14 here and I'm thinking it can take a shot at .25. Here is some DD and if you look at the L2 you can see there isn't much resistance up ahead. The company has secured financing and I feel news is close now.
Here is some DD:
Website: http://www.bluespherecorporate.com
Phone: + 972-9-8917438
Email: info@bluespherecorporate.com
Blue Sphere Corporation is focused on preventing greenhouse emissions while turning waste into revenue generating resources including:
Energy
Compost
Carbon Credits
The Company is focused on the waste disposal, dairy and animal manure industries with a very high IRR and continuous revenue for long periods of time.
The Company has signed 7 projects and is starting to execute them now.
We have completed financing of $3.4 MM for the first two projects.
We have a pipeline of 4 projects in the United States, 14 in China and 1 in Canada.
We expect to start generating revenues in the coming 12-18 months.
http://www.bluespherecorporate.com/blsp_press.html
http://www.otcmarkets.com/stock/BLSP/financials
Chinese Projects
Blue Sphere has a partnership with Clinci-a leading provider of waste to energy and waste to compost solutions-to develop pro-jects in China.
14 projects in the pipeline with total expected power production ca-pacity of 70 MW.
In return for exclusive rights, Blue Sphere executes the project and provides the investment to build and operate the project.
Blue Sphere's Revenue Stream
Blue Sphere generates revenue through:
Project Development fees
Ongoing sales of carbon credits directly to major corporations On the carbon credit exchange Ongoing sales of thermal and electrical Energy and
Ongoing sales of byproducts.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68718782 Thanks ALiVE.
Chart:
http://stockcharts.com/c-sc/sc?s=BLSP&p=W&yr=2&mn=3&dy=0&i=p06541451897&a=248057352&r=3290
Board: http://investorshub.advfn.com/boards/board.aspx?board_id=17803
MOMO'S BREAKOUT BOARD. MFTH. High Bounce Alert.
http://investorshub.advfn.com/boards/board.aspx?board_id=4929
Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
JERUSALEM, November 4, 2011 /PRNewswire/ --
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has pre-paid two convertible promissory notes aggregating $57,000, including the interest due.
The notes beared interest at 8% per annum and were due in August , 2011 and in October , 2011. The notes had conversion rights allowing the holder of the note at any time to convert all or any part of the remaining principal balance into the Company's common stock at a price equal to 58% of the average of the lowest three trading prices for the Common Stock during the most recent ten-day period.
The note was issued to fund development of Medisafe 1's patented life-saving technology and to assist in ongoing business development. As a result of pre-payment, the non-affiliated third party lender has released Medisafe 1 Technologies from its obligation. "Medisafe 1 pre-paid the promissory notes to prevent the notes from being converted into equity," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "Pre-payment of the notes prevented and continues to prevent the dilution of our common stock."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient
EPIC STOCK ALERTS. MILV.
http://investorshub.advfn.com/boards/board.aspx?board_id=14660
MILV added .Looks like very good accumulation and a break of .10 could send it flying much higher
MICRO Insider. END. Insider Purchase.
http://investorshub.advfn.com/boards/board.aspx?board_id=17034
END--ceo purchased 10k shares at $7.13. Stock trading at $7.48. This is an oldie, but goodie! Do your own research.
insider data provided by www.scumfish.com
Endeavour International Corporation (Endeavour) is an independent oil and gas company engaged in the exploration, development and acquisition of energy reserves in the United States and United Kingdom. The Company has four producing fields in the United Kingdom, including Alba, Bittern, Enoch and Goldeneye. The Goldeneye field represents nearly all of its gas production in the United Kingdom. As of December 31, 2009, Endeavour had proved reserves of 89,100 million cubic feet (MMcf) of natural gas and 3,366 thousands of barrels (Mbbls) of crude oil for a combined18, 216 million barrels of oil equivalent (MBOE). On May 14, 2009, Endeavour completed the divestiture of its Norwegian subsidiary, Endeavour Energy Norge AS, to VerbundnetzGas AG, a German utility company
no i live in managua..went up to waslala where the farm is near..but stayed in waslala never went to the farm
STOCK LEGENDS. ATTD. Sample Products.
http://investorshub.advfn.com/boards/board.aspx?board_id=20989
Once again CURX has lived up to the bio hype most of them do , we have record volume and holding nice gains. This company will be holding their shareholders meeting tomorrow , this should stay on your watch list for any sizable pull back.As I write this we are seeing the little resistance at .14 being bought up. Have a great trading day and keep in touch
STOCKGOODIES PLAYS OF THE WEEK. CURX.
http://investorshub.advfn.com/boards/board.aspx?board_id=18582
Once again CURX has lived up to the bio hype most of them do , we have record volume and holding nice gains. This company will be holding their shareholders meeting tomorrow , this should stay on your watch list for any sizable pull back.As I write this we are seeing the little resistance at .14 being bought up. Have a great trading day and keep in touch
low Float Stock Plays. EAPH. Up 21%.
http://investorshub.advfn.com/boards/board.aspx?board_id=17970
On vacation. What did you do - go into town?
On a new board. STOCK BADDIES.
http://investorshub.advfn.com/boards/board.aspx?board_id=22617
hi guys..was on vaction last week..here is too nappers for u..conz and vshc..they just might wake up soon
MOMO'S BREAKOUT BOARD. ECDC. MASP.
http://investorshub.advfn.com/boards/board.aspx?board_id=4929
..................................................................
ECDC(0.0061)CEO of twitter is on ECDC board now$$$
>>major DD>>BIG DEALS are coming (MTV,VH1 ..)
the acquisition of Rogue Paper and their expertise in the mobile industry is going to be a game changer for ECDC and its shareholders because of the potential partnerships that may be developed through the high caliber contacts this deal could bring.
CEO of twitter is on board as an advisor. Check the enclosed link and the links attached:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67655286
The acquisition of mobile and social media developer Rogue Paper would bring in deals with MTV, VH1, and NCAA sport teams
ROGUE PAPER DD
Based in California, Rogue Paper (www.roguepaper.com) is a developer of mobile and media applications, which current has products and partnerships with some very well known media companies.
TV Tune-In Application
TV Tune-In, developed by Rogue Paper, is a real-time, companion viewing and mobile app development platform for media companies to help drive viewership, conversation and interactions for television shows and content. TV Tune-In's CMS allows media companies to develop branded iPhone and iPad apps for television shows and channels. The apps aims to attract fans around live viewing of their favorite show, event, or sports team. Users can actively comment, Tweet and Like their favorite show, chat with friends, play trivia games, watch exclusive video content, photos and more. www.tvtunein.com
Current TV Tune-In Clients
The Company has developed products such as MTV's WatchWith using their TV Tune-In platform, and VH1 for their VH1 Co-Star app, which both allow users and viewers to interact, in real-time, with other fans during live TV shows.
Live Sports Fan App
In March 2011, Rogue Paper partnered with Duke University Athletics to release the Duke GameTime app, which allows fans of Duke Men's and Women's basketball to read news, see schedules and scores, and send invites to friends to watch and comment along with games, together. Designed as a fan's second-screen companion to live-broadcast postseason games, the app allows users to "Tune-In" to a curated messaging stream, like a version of Twitter targeted toward the game.
Powered by Rogue Paper's TV Tune-In platform, the stream improves the game viewing experience by allowing for a community driven watching experience, and brings the fans exclusive commentary from the people closest to the action.
Impressive Board
One of the key aspects to any partnership or merger between EarthSearch and Rogue Paper is the quality board of advisors that any deal could bring to the table. More information on their board of advisors can be found here http://www.roguepaper.com/tv-tune-in-lets-big-media-jump-on-the-audience-interactivity-bandwagon
with 180 million O/S ECDC is going to run fast when a monster deal is announced
.................................................................
MASP(0.003)reinstated &BIG insiders Buying@ 0.0043 !! >>>
REINSTATEMENT 11/03/2011 !!!!
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=XKdi74XL4TENlrpuK%252bc57A%253d%253d&CorpName=MASS+PETROLEUM+INC.
MASP president buying 21 million shares @0.0043!!!
link:
http://ih.advfn.com/p.php?pid=nmona&article=48867690
pinksheets.com new filings in October 2011
http://www.otcmarkets.com/stock/MASP/financials
MASP info >>>>
http://www.masspetroleum.com/
MASS Petroleum is an oil and gas production company backed by an experienced and dedicated management team. Mass Petroleum is engaged in the acquisition of producing oil and gas projects to build its reserves and ensure sustainable growth by focussed exploration and acquisition strategy to create shareholder value.
MASS Petroleum is currently in the process of acquiring several producing oil and gas assets in Western Canada. The target acquisitions offer a stable production base with low risk drilling opportunities. This provides steady cash flow for continued exploration and development in various prospect areas within the Western Canadian Sedimentary Basin. Canada's proven oil reserves are well developed and holds more than 175 billion barrels of oil. The area is politically stable and has been a major oil producer of many decades.
MASS Petroleum's primary objective is to:
- Make strategic acquisitions balanced with a focused exploration and development plan
- Building core areas with significant undeveloped land, high working interest and/or operatorship
- Balanced light oil and gas portfolio with large scalable reserves
- Focus on high Working Interest (WI) projects will upside drilling prospect.
looking for news soon
MICRO Insider. EGHT. Insider Purhase.
http://investorshub.advfn.com/boards/board.aspx?board_id=17034
EGHT--Insider purchased 41,480 shares at $3.71. Stock closed at $3.67. Do your own research.
insider data provided by www.scumfish.com
8x8, Inc. (8x8) develops and markets telecommunications services for Internet protocol (IP), telephony and video applications, as well as Web-based conferencing and unified communications services, managed hosting and cloud-based computing services. The Company offers the 8x8 Virtual Office hosted private branch exchange (PBX) service, 8x8 Complete Contact Center service, 8x8 Trunking service, 8x8 Hosted Key System service, 8x8 MobileTalk service, 8x8 Virtual Meeting Web conferencing service, 8x8 Virtual Office Pro unified communications solution and 8x8 Managed Hosting and Cloud-Based Computing Solutions. In May 2010, it acquired Central Host, Inc., a provider of managed hosting and cloud-based computing solutions and began offering 8x8 Managed Hosting and Cloud-Based Computing solutions to business customers. On June 17, 2011, 8x8 acquired Zerigo, Inc. In September 2011, the Company acquired Contactual, Inc.
Pro Traders Forum. AGMC.
http://investorshub.advfn.com/boards/board.aspx?board_id=18631
This could make for a very interesting bottom play
DD_YOU http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68733140
sc
---------------------------------------------
Replies to this email will be sent directly to the board moderator at SuperC55@hotmail.com.
Estrella'sSizzlingHotStockPlays. StockO'holicsInvestingUniversity. CURX/QB:
http://investorshub.advfn.com/boards/board.aspx?board_id=21178
http://investorshub.advfn.com/boards/board.aspx?board_id=5322
CURX ~Curaxis Pharmaceutical Corporation~ dd
CURX.OB (Frankfurt: 8CX)
The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be
held on November 8th 2011. Please click here to download the proxy materials
and to vote:
[1]https://www.iproxydirect.com/index.php/CURX
About CURX.OB (Frankfurt: 8CX)
Curaxis Pharmaceutical Corporation is an emerging specialty pharmaceutical
company with a hormone drug product candidate for the treatment of Alzheimer's
disease and multiple cancers. Curaxis' therapeutic platform is based on the
hypothesis that many diseases of aging may be caused by age-related changes in
the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is
a hormonal endocrine feedback loop that controls development, reproduction and
aging in animals. This drug development platform is built on the premise that
hormones associated with this feedback loop are beneficial early in life, when
they promote growth and development, but are harmful later in life when the
mechanism for feedback is compromised, thereby leading to disease processes,
including pathologies associated with Alzheimer's disease and various cancers.
Click Here For Video: [2]http://blog.curaxispharma.com/media/
[3][rjqljCapture10.GIF]
CURX Security Details
Curaxis Pharmaceutical Corporation is a fully reporting SEC company, publicly
traded on the OTC Market under the symbol, "CURX", and within the OTCQB market
tier. As such, Business, operational and financial information on CURX is fully
transparent and available to public view.
Visit [4]http://www.otcmarkets.com/stock/CURX/quote for more information.
Market Value1 $5,357,650 a/o Nov 03, 2011
Shares Outstanding 76,537,861 a/o Aug 11, 2011
Float 16,238,300 a/o Sep 15, 2010
Authorized Shares 480,000,000 a/o Aug. 12 2011
Par Value 0.0001
(per otcmarkets)
Per FORM 10Q link listed below
As of August 11 , 2011, there were 76,537,861 shares outstanding of the
registrant's common stock.
Common stock, $0.0001 par value; 480,000 authorized; 72,216 and 76,474 shares
issued and outstanding at December 31, 2010 and June 30, 2011, respectively.
Transfer Agent
Direct Transfer, LLC.
500 Perimeter Park Drive Suite D
Suite D
Morrisville, NC, 27560
919-481-4000
www.issuerdirect.com
ta@issuerdirect.com
10Q reported Aug 12, 2011 period ending Jun 30, 2011
[5]http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721
Shareholders of Record: 41 a/o Apr 15, 2010
SIC - Industry Classification: 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc.: 2008 and On July 30, 2010, the Company entered into an agreement
and plan of merger with Curaxis Pharmaceutical Corporation, a Nevada
corporation formed solely for the purpose of a name change. Pursuant to the
Short-Form Merger, the Company changed its name to Curaxis Pharmaceutical
Corporation ("Curaxis" or the "Company")
In February 2011, the Company was granted approval and listed its stock to
trade on the Frankfurt stock exchange ("FSE") under the symbol 8CX to expand
its global capital markets access.
Security Notes
Capital Change=shs increased by 91 for 1 split. Ex-date=01/12/2010. Rec
date=12/09/2009. Pay date=01/11/2010
Company Notes
Formerly=Auto Search Cars, Inc. until 9-2010
Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com
CURX Products & Services
CURX Pipeline
Our therapeutic platform is based on the hypothesis that many diseases of aging
may be caused by age-related dysregulation of the
hypothalamic-pituitary-gonadal (HPG) axis. This platform is built on the
premise that hormones associated with this axis are beneficial early in life,
when they promote growth and development, but are harmful later in life when
the mechanism for feedback is compromised, thereby leading to disease
processes, including pathologies associated with Alzheimer's disease and
various cancers. We believe our discovery of a duplicate HPG axis at the
cellular level in brain tissue from Alzheimer's patients and in multiple tumors
will enable us to develop significant new treatments for Alzheimer's disease as
well as many cancers.
CURX Alzheimer's Disease Program
Leuprolide acetate, a peptide hormone, has been widely used over the past
twenty years for the treatment of a number of hormone-related disorders, most
notably prostate cancer and endometriosis and precocious puberty, and has a
well-established safety profile. Voyager has conducted extensive preclinical
and clinical studies exploring the use of leuprolide acetate for the treatment
of Alzheimer's disease in mild-to-moderate patients. The results to date are
very encouraging and point especially to a potentially significant new
treatment for women with Alzheimer's disease.
Women represent approximately two-thirds of Alzheimer's patients. Men present
greater challenges in the use of leuprolide to treat Alzheimer's disease
because leuprolide suppresses their production of testosterone, which could
necessitate patient self-administration of supplemental testosterone and which
can lead to wide swings in testosterone blood serum levels. Therefore, in the
near-term, we plan to concentrate our development efforts on the use of
leuprolide acetate to treat women, although we will continue our efforts to
better understand mechanisms that might lead to optimum outcomes in men.
This Video is Patrick Smith Of Curaxis Pharmaceutical Corporation - Alzheimer
Disease
Lists him as CEO but he is no longer the CEO, but it explains Alzheimer's and
the company Brilliantly!
[6][gif]
[7]http://www.youtube.com/watch?v=XdMmQ6ppDnU
CURX Oncology Program
We have conducted an extensive preclinical research program in the use of
leuprolide acetate to treat a number of cancers, including hor mone refractory
prostate cancer, brain cancers, kidney cancer, pancreatic cancer and
non-small-cell lung cancer.
Our work in oncology is based on new insights into the growth of cancer cells
that have been discovered by our scientists. In particular, our scientific
findings relating to autocrine-paracrine signaling and the replication of the
hypothalamic-pituitary-gonadal axis (the HPG axis) inside of cancer cells point
to a previously unknown mechanism that drives the growth of cancer cells and an
entirely new method of attacking those cancer cells; i.e., using high doses of
leuprolide acetate to eliminate the gonadotropins that may be driving the
growth of those cells.
Our preclinical testing of this new treatment approach has produced extremely
encouraging results. In both in vitro and in vivo experiments, we have
demonstrated a potentially important new therapy for the treatment of a number
of cancers.
We plan to use the same compound for our various cancer Phase II clinical
trials as we are using for clinical trials of VP4896. Since we have completed
Phase I safety trials of VP4896, we believe that we will be able to commence
our clinical programs for various cancers with Phase II clinical trials instead
of Phase I safety trials. However, the FDA will have to agree to the
commencement of these clinical programs with Phase II clinical trials when we
submit our Investigational New Drug Applications, or INDs, to the FDA.
History
Curaxis' history dates to an insight from the mid-1990's concerning how changes
in various hormone levels impact our health as we age. Most everyone knows
that, as we age, our hormone levels change. In particular, it is well known
that as we age, levels of estrogen decline precipitously in women, leading to
menopause, and levels of testosterone gradually decline in men, leading to
andropause. However, while a great deal of research has previously been devoted
to the effects of declining estrogen and testosterone on our health, including
our mental abilities, Curaxis has taken this research in a broader direction.
Specifically, Curaxis was founded in 2001 (as Voyager Pharmaceutical Corp.) to
take a step back from a singular focus on estrogen and testosterone to examine
the entire HPG axis, which regulates production of estrogen and testosterone
throughout our lives. Curaxis' initial hypothesis was that changes in the
levels of hormones in this axis other than estrogen and testosterone play a key
role in various diseases of aging. During 2001 and the years that immediately
followed, Curaxis devoted substantial research to testing this hypothesis. Also
during 2001, Curaxis was awarded a broad patent covering its unique approach to
the treatment of Alzheimer's.
As a result of Curaxis' research, it became increasingly clear that one hormone
of the HPG axis, called luteinizing hormone or LH, may play a central role in
the pathologies that lead to Alzheimer's as well as other diseases of aging,
including many cancers. Levels of LH increase dramatically as women enter
menopause and increase substantially in men as they age and testosterone
production declines. In numerous preclinical studies, Curaxis' research showed
that these increased levels of LH were likely a key contributor to developing
Alzheimer's.
Developing A Focus
Having determined that high levels of LH represented a potential cause of
Alzheimer's, Curaxis then focused on using leuprolide acetate, which eliminates
or dramatically reduces LH levels, as a treatment for Alzheimer's. Curaxis'
focus on LH followed two parallel paths.
First, in 2002, Curaxis entered into an agreement with Durect Corporation to
develop a proprietary implant that would release leuprolide acetate at targeted
levels over a two month dosing period. Work on development of this implant
commenced in 2002 and culminated in 2005 with a successful Phase 1 trial of the
safety and tolerability of the implant.
Second, because leuprolide acetate had been used for many years to treat other
diseases, including prostate cancer, in early 2003 Curaxis commenced a Phase 2
clinical trial to treat mild-to-moderate Alzheimer's in women, using a
commercially available dose of leuprolide. In addition, in late 2003 Curaxis
commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer's in
men, again using a commercially available dose of leuprolide.
This parallel path enabled Curaxis to significantly shorten development for its
Alzheimer's candidate. As a result, by mid-2005, Curaxis had successfully
completed dosing in the Phase 1 trial of its proprietary implant developed with
Durect, which Curaxis calls Memryte, and had also completed its Phase 2 trial
of leuprolide in women. The results of both of these trials were encouraging
and Curaxis began making plans for Phase 3 trials of Memryte. Based on FDA
filings and a meeting with the FDA in August 2005, Curaxis launched its Phase 3
trials of Memryte in September 2005.
Also in September 2005, Curaxis (then Voyager Pharmaceutical) filed for its
initial public offering, in order to raise sufficient funds for its Phase 3
trials. Based on the strength of its preclinical and clinical data and its
management, it was anticipated that a successful IPO would follow later in
2005. Unfortunately, a leading contributor to the research and a significant
shareholder of the company took medical leave at the height of these efforts.
Complications associated with his illness and absence forced the company to
withdraw from the IPO process.
Initial Results
The results of the Phase 2 clinical trial in men were obtained in mid-2005.
However, although there were positive signals in those results, the results
were confounded by the need to provide supplemental testosterone to men on
active treatment in the trial.
During 2006, Curaxis renewed its efforts to obtain private capital to complete
its Phase 3 trials. Although it enjoyed some success, it was unable to obtain
the full amount needed and was forced to terminate the Phase 3 trials in late
2006. During the remainder of 2006 and 2007, Curaxis worked to obtain the
maximum amount of data from these terminated trials. Although the data was
incomplete due to the early termination of the trials, the date obtained
provided further support for the use of leuprolide to treat mild-to-moderate
Alzheimer's, particularly in women.
During 2008 and 2009, Curaxis has regrouped in its efforts to move forward with
Memryte. Although Curaxis was unable to make progress in the clinical
development of Memryte during this period, the field of Alzheimer's research
was not static during this period. A number of Phase 3 Alzheimer's trials,
which focused on a target called beta amyloid to treat Alzheimer's, failed to
meet their endpoints during 2007-2009. Curaxis has long believed that a focus
solely on beta amyloid as a target to treat Alzheimer's is incorrect and the
failures of these trials support that view. Most importantly, Curaxis believes
that the failure of these trials will broaden acceptance of other approaches to
treating Alzheimer's, including Curaxis' approach.
In 2009, Curaxis entered into a series of agreements with Southridge Business
Solutions Group ("Southridge") in order to restructure its balance sheet and
establish a trading market for its common stock. Under the terms of those
agreements, Southridge assisted Curaxis in negotiating settlements with its
creditors to eliminate or substantially reduce and defer its trade debt. To
date, Curaxis has realized reductions in excess of $6 million in liabilities as
the result of the combined efforts. In addition, Southridge assisted Curaxis in
securing a $25 million equity facility under which the Company can
periodically, over a period of three years, sell up to $25 million of its
common stock to an affiliate of Southridge. On December 8, 2010, the Company
filed a Registration Statement on Form S-1 to register 13,000,000 shares of
common stock to be reserved for issuance under the Equity Line Facility.The
proceeds of the equity facility will be used, in part, to fund the next steps
in the Company's clinical development plan.
In July, 2010, Curaixs completed a reverse merger into a public shell
Corporation. As a result, the Company's common stock is now traded on the OTC
Quote Board under the symbol "CURX." In addition, Curaxis began trading on the
Frankfurt Stock Exchange under the ticker "8CX" on February 7, 2011.
On June 27, 2011, the Company announced changes to its Board of Directors (the
"Board") and its executive management team to better position the Company for
its next phase of growth and development. The new Board has a wealth of
experience and comprehensive knowledge of life sciences, operations and
strategic management in the area of pharmaceuticals. In addition, the newly
appointed Board members have significant experience in all of the necessary
industry arenas to execute the Company's business plan on an accelerated basis.
Going Forward
The Board is in the process of completing a comprehensive analysis of the
financial position of the Company and is evaluating potential funding
alternatives. In addition, the Board has been focused on several remaining
transition items including, but not limited to, the efficient processing of
capital transactions for pre-merger shareholders, the scientific evaluation of
the Company's inventory of pre-clinical and clinical data and related
intellectual property and, the development of strategic alternatives.
DOWNLOAD: Alzheimers Research Report (PDF)
[8]http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf
BLOGS [9]http://blog.curaxispharma.com/
Milestones:
[10]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
2&Itemid=69
Links:
[11]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
4&Itemid=71
Reference:
[12]http://www.curaxispharma.com/index.php?option=com_content&view=article&id=5
5&Itemid=72
CURX Partners
Curaxis has engaged a very impressive infrastructure of scientific/technical,
medical and legal advisers as strategic partners. This allows the Company to
leverage talented individuals who provide key knowledge, expertise and support.
A selection of these partnerships is represented by:
Our collaboration in discovery research with leading Alzheimer's research
teams led by George Perry, PhD, Mark A. Smith, PhD
([13]http://www.cwru.edu/med/pathology);
Leading patent and FDA legal support from Covington & Burling
([14]http://www.cov.com);
Clinical and FDA regulatory support from Bert Spilker & Associates
([15]http://www.bertspilker.com);
Drug development and delivery support from DURECT Corporation
([16]http://www.durect.com);
Website and marketing communications support by Sage Communications, LLC.
([17]http://www.aboutsage.com)
Case Western Reserve University - Department of Pathology
World-class research is conducted in the Department of Pathology with major
emphasis on the following areas and more: cancer biology, infection and
immunity, neurobiology/neuropathology, tissue injury and healing, and
biomaterials biocompatibility. These emphasis areas are reflected in the three
tracks of the Pathology Graduate Program: the Cancer Biology Training Program
(CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular
Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program
provides extensive opportunities for PhD or MD-PhD training in these areas. A
separate program leads to the MS degree.
Covington & Burling LLP
Covington & Burling LLP represents clients in cutting-edge technology,
litigation, white collar defense, transactional, governmental affairs,
international, life sciences and other matters. In responding to the needs and
challenges of our clients, our lawyers draw upon the firm's expertise and
experience in a broad array of industries to provide solutions to difficult,
complex, and novel problems and issues, whether in litigation, transactions, or
regulatory proceedings.
Bert Spilker & Associates
The mission of Bert Spilker & Associates (BS&A) is to provide clients with the
highest quality, most cost-effective, and timely pharmaceutical consulting
services available. To achieve this goal, Bert has assembled a group of over
150 independent associates who are available to assist him in most aspects of
drug discovery, drug development and strategy setting. BS&A strives to build
long-term relationships with clients based on knowledge of his clients culture,
research, products and services.
Sage Communications Advertising and Public Relations
Sage Communications is a full-service, integrated marketing firm that provides
advertising, public relations, and strategic marketing services to clients from
across the street to across the globe, from emerging start-ups, to major
Fortune 500 companies. Throughout our history, our mission has remained the
same: Align marketing strategy to directly impact our clients' bottom line. We
are located in Tysons Corner, VA
CURX Recent News
RED HOTT
The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be
held on November 8th 2011.
Quote:
___________________________________________________________________________
Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company
dedicated to finding cures for major age-related diseases. Curaxis' initial
focu s is Alzheimer's Disease (or AD). The lead product is a patented
treatment, Memryte, that has shown the potential for treating and halting the
progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer's Association,
"Changing the Trajectory of Alzheimer's Disease: A National Imperative" shows
that in the absence of disease-modifying treatments, the cumulative cost of
care for people with Alzheimer's from 2010 to 2050 will exceed $20 trillion in
today's dollars.
The new report is not all bad news, however, as it shows that Medicare and
Medicaid can achieve dramatic savings - and lives could be significantly
improved - with even incremental treatment improvements.
Harry John's, President & CEO of the Alzheimer's Association said, " Today,
there are NO treatments that can prevent, delay, slow or stop the progression
of Alzheimer's disease. While the ultimate goal is a treatment that can
completely prevent or cure Alzheimer's, we can see that even modest
improvements can have a huge impact."
Market Need - Curaxis Solution
Currently marketed Alzheimer's drugs target the symptoms of Alzheimer's disease
by enhancing some patients' cognitive function and general behavior, but
generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors -
current theory) experience a modest improvement in cognitive function.
According to the Alzheimer's Association, for those patients who show
improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes
that Memryte may substantially slow the progression of Alzheimer's disease and
represent a significant clinical improvement over current drugs.
___________________________________________________________________________
Aug 17, 2011 Curaxis Pharmaceutical Corporation Management Working Through
Transition Phase and Evaluating Alternatives
Jun 27, 2011 Curaxis Pharmaceutical Corporation Announces Key Changes to Its
Board of Directors and Management Team in Progression Toward Clinical Trials
May 10, 2011 Curaxis Pharmaceutical Corporation Chief Executive Officer
Comments on Recent NIH Research
May 5, 2011 Curaxis' Memryte Named One of the Top 100 Drugs in Development
Today by R&D Directions
Mar 24, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent Prana Research
Mar 10, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as
Patents End"
Feb 14, 2011 Curaxis Pharmaceutical Corp. to Meet With Ticino Business
Development Office in Lugano, Switzerland
Feb 9, 2011 Curaxis Pharmaceutical Corp. Announces New Listing on the Frankfurt
Stock Exchange
Feb 7, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on
Recent Alzheimer's Association Report
Feb 3, 2011 Curaxis Pharmaceutical Management on Roadshow in Europe to Access
Capital & Pursue Strategic Partners
CURX Core Management Team
Timothy R. Wright - Chairman and Interim Chief Executive Officer
A seasoned executive with over 25 years of life sciences experience, Timothy
Wright has comprehensive operating and strategic management experience, which
encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical
services. Prior to joining Curaxis as Chairman of the Board and interim Chief
Executive Officer, Mr. Wright was a Senior Vice President and President of the
pharmaceuticals division at Covidien (Mallinckrodt). He previously served as
President of Global Operations at Elan BioPharmaceuticals and spent 17 years at
DuPont Merck Pharmaceuticals, where he was classically trained in the
pharmaceutical industry. He brings significant global operating and product
launch experience and has served on the boards of four public and four private
global life sciences companies.
Judith S. T. Geaslen - VP Finance
Judith S. T. Geaslen has been the Company's Vice President of Finance and Chief
Accounting Officer since August 2009 after serving as Corporate Controller and
Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served
as Vice President and Corporate Controller at Wilmington Trust Corporation, a
financial holding company engaged in providing a range of banking and other
financial services through its banking and other subsidiaries, and from 1994 to
1999, served as Vice President and Manager of the Asset Review Division. From
September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a
registered public accounting firm, mostly recently serving as Audit Senior
Manager. Ms. Geaslen is a graduate of Saint Mary's College, Notre Dame,
Indiana.
CURX Contact Info
Curaxis Pharmaceutical Corp
1004 Chagford Way
Raleigh, NC 27614
Website: [18]http://www.curaxispharma.com
Phone: 888-919-2873
Email: jgeaslen@curaxispharma.com
twitter: [19]http://twitter.com/#!/curaxispharma
facebook:
[20]http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/1591043041
05704
As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile,
Always do your own Due Diligence
Sources: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CURX website,
www.businessweek.com
(these are only sources and not always up to date)
___________________________________________________________________________
1 day + weekend Awareness Profile
StockGoodies.com [21] [jpeg]
disclaimer: [22]http://www.stockgoodies.com/terms_of_use.php
Email: nilbud@stockgoodies.com // Website: [23]http://www.stockgoodies.com
[24][jpeg] [25] [jpeg] [26] [jpeg]
References
1. https://www.iproxydirect.com/index.php/CURX
2. http://blog.curaxispharma.com/media/
3. http://blog.curaxispharma.com/media/
4. http://www.otcmarkets.com/stock/CURX/quote
5. http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721
6. http://www.youtube.com/watch?v=XdMmQ6ppDnU
7. http://www.youtube.com/watch?v=XdMmQ6ppDnU
8. http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf
9. http://blog.curaxispharma.com/
10. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=52&Itemid=69
11. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=54&Itemid=71
12. http://www.curaxispharma.com/index.php?option=com_content&view=article&id=55&Itemid=72
13. http://www.cwru.edu/med/pathology);
14. http://www.cov.com%29%3B/
15. http://www.bertspilker.com%29%3B/
16. http://www.durect.com%29%3B/
17. http://www.aboutsage.com%29/
18. http://www.curaxispharma.com/
19. http://twitter.com/#!/curaxispharma
20. http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/159104304105704
21. http://www.stockgoodies.com/
22. http://www.stockgoodies.com/terms_of_use.php
23. http://www.stockgoodies.com/
24. http://investorshub.advfn.com/boards/board.aspx?board_id=18582
25. http://www.facebook.com/StockGoodies
26. http://twitter.com/#!/StockGoodies
Alerts,Charts, &Hot Stocks. Welcome ToThe Zoo. CURX. Monday!
http://investorshub.advfn.com/boards/board.aspx?board_id=15004
http://investorshub.advfn.com/boards/board.aspx?board_id=16722
$CURX .066 on alert for Monday!!!!
Curaxis Pharmaceutical Corp OTCQB
http://www.curaxispharma.com/
Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. We believe our discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer's disease as well as many cancers.
Share Structure
Shares Outstanding 76,537,861 a/o Aug 11, 2011
Float 16,238,300 a/o Sep 15, 2010
Authorized Shares 480,000,000 a/o Sep 15, 2010
http://www.otcmarkets.com/stock/CURX/news
http://www.otcmarkets.com/stock/CURX/financials
Management
Curaxis Pharmaceutical is built on its science, its people, and its strategic relationships.
Over the past decade, there has been a dramatic shift in the approach to developing pharmaceuticals. The concept of growing a large and costly infrastructure internally has been replaced with outsourcing and employing CROs. Curaxis Pharmaceutical Corp. is employing this model in order to quickly advance towards commercialization, while carefully managing costs.
Core Management
Timothy R. Wright - Chairman and Interim Chief Executive Officer
Judith S. T. Geaslen - Vice President - Finance
Timothy R. Wright - Chairman and Interim Chief Executive Officer
A seasoned executive with over 25 years of life sciences experience, Timothy Wright has comprehensive operating and strategic management experience, which encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical services. Prior to joining Curaxis as Chairman of the Board and interim Chief Executive Officer, Mr. Wright was a Senior Vice President and President of the pharmaceuticals division at Covidien (Mallinckrodt). He previously served as President of Global Operations at Elan BioPharmaceuticals and spent 17 years at DuPont Merck Pharmaceuticals, where he was classically trained in the pharmaceutical industry. He brings significant global operating and product launch experience and has served on the boards of four public and four private global life sciences companies.
Judith S. T. Geaslen - VP Finance
Judith S. T. Geaslen has been the Company's Vice President of Finance and Chief Accounting Officer since August 2009 after serving as Corporate Controller and Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served as Vice President and Corporate Controller at Wilmington Trust Corporation, a financial holding company engaged in providing a range of banking and other financial services through its banking and other subsidiaries, and from 1994 to 1999, served as Vice President and Manager of the Asset Review Division. From September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a registered public accounting firm, mostly recently serving as Audit Senior Manager. Ms. Geaslen is a graduate of Saint Mary's College, Notre Dame, Indiana.
Board Of Directors
Board Of Directors
Timothy R. Wright - Director and Interim Chief Executive Officer
Michael W. George - Director
K. Ivan F. Gothner - Director
Stephen J. Leary - Director
Michael R. Miller - Director
Terrance Novak - Director
Dr. Bert Spilker - Director
About Timothy Wright
A seasoned executive with over 25 years of life sciences experience, Timothy Wright has comprehensive operating and strategic management experience, which encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical services. Prior to joining Curaxis as Chairman of the Board and interim Chief Executive Officer, Mr. Wright was a Senior Vice President and President of the pharmaceuticals division at Covidien (Mallinckrodt). He previously served as President of Global Operations at Elan BioPharmaceuticals and spent 17 years at DuPont Merck Pharmaceuticals, where he was classically trained in the pharmaceutical industry. He brings significant global operating and product launch experience and has served on the boards of four public and four private global life sciences companies.
About Michael George
Michael George is Chief Executive Officer of Michael George & Associates, a multi-faceted consulting firm specializing in turnarounds for pharmaceutical companies, which he founded in 2002 and re-established in 2006. Previously, he served as Executive Vice President of aaiPharma Inc. Mr. George brings over 35 years of experience in the pharmaceutical industry in senior management positions at companies including Elan Pharmaceuticals, Urocor, Inc., and the DuPont Merck Pharmaceutical Company. Earlier in his career, he held product management and sales and marketing roles at the Bristol Myers Pharmaceutical Company, Sandoz Pharmaceutical, Inc., and McDonnell Douglas Corporation.
About Ivan Gothner
Ivan Gothner is Managing Director and founder of Adirondack Partners, LLC, a private merchant banking firm. Mr. Gothner's work has focused on small and mid-size companies experiencing rapid growth as a result of introducing new technologies and products or by entering new markets. Prior to founding Adirondack in 1992, he was a Senior Vice President at Barclays Bank and spent four years at Kleinwort Benson Limited, where he acted as General Manager of the KB Mezzanine Fund LP, a specialized fund which invested in the equity and junior capital of small and mid-sized businesses. Mr. Gothner has been a major investor and active member of the Board of Directors of various portfolio companies, and acted as a "start-up" executive for a European medical device company entering the U.S. market. He currently serves on the Board of Directors of AgFeed Industries, Inc., Covenant Group of China, Inc. and ArtID, LLC.
About Stephen Leary
Stephen Leary is a Principal of Professional Management of Raleigh, Inc., a medical practice management and financial consulting firm based in Raleigh, NC. A Certified Healthcare Business Consultant (CHBC), Mr. Leary has been with Professional Management since 1979 and currently works with physicians, dentists, group practices and hospitals in North Carolina and Southern Virginia. Mr. Leary brings over 35 years of experience and has held numerous positions at companies including Kenrex Labs (a division of Bausch & Lomb), A-T-O, Inc. and the Drug Enforcement Agency (DALE). He currently serves as President of the Board of the National Society of Certified Health Care Business Consultants and has served on the Board of major national healthcare organizations such as the National Association of Health Care Consultants (NAHCC) and the Society of Professional Business Consultants, among others.
About Michael Miller
Michael Miller brings 26 years of experience with DuPont de Nemours & Company and The DuPont Merck Pharmaceutical Company, where he has held numerous corporate finance and management positions. Prior to retiring in 1999, Mr. Miller was Senior Vice President and Chief Financial Officer of the DuPont Merck Pharmaceutical Company. He currently provides financial consulting services and works part-time as the CFO of the Delaware Art Museum. Mr. Miller also serves as a member of the Board of Directors of Urocor, Inc., the Board of Trustees of the Boys & Girls Club of Delaware, and the Board of Directors of Christiana Care Health System.
About Terence Novak
Terence "Terry" Novak has over 30 years of experience in the pharmaceutical and biotech industries, including 20 years in executive leadership in business development, sales and marketing, and manufacturing operations. Currently, Mr. Novak is President of Norwich Pharmaceuticals, a comprehensive global provider of contract development and manufacturing services, and President and Chief Executive Officer of Frontline Pharmaceuticals, a start-up specialty pharmaceutical company. Previously, Mr. Novak served as President of North America and Chief Commercial Officer at Patheon, Inc. and President of DSM Pharmaceuticals. He has also held various senior healthcare management positions at companies including Cytogen, Algos Pharmaceuticals, and Innovex, a division of Quintiles Transnational and various sales and marketing positions at Bristol-Myers Squibb. Mr. Novak is a highly regarded speaker at industry conferences and serves on the Editorial Advisory Board of Contract Pharma magazine and the Board of Directors at Frontline Pharmaceuticals.
About Dr. Bert Spilker
Bert Spilker, PhD, MD, FCP, FFPM, is an independent consultant who works with a large number of pharmaceutical, biotech and medical device companies, primarily in the areas of regulatory affairs, clinical trials and development. Prior to Curaxis, Dr. Spilker was most recently the Senior Vice President of Scientific and Regulatory Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, he was President and Co-founder of Orphan Medical, Inc., a public pharmaceutical company that develops and markets important medical products for patients with uncommon diseases, where he brought seven drugs to the market. Dr. Spilker has over 20 years of experience working at major pharmaceutical companies including Pfizer, Philips-Duphar, Sterling-Winthrop and Burroughs Wellcome. He is Clinical Professor of Pharmacy Practice at the University of Minnesota and Adjunct Professor of Medicine and Clinical Professor of Pharmacy at the University of North Carolina in Chapel Hill. Dr. Spilker is also well known as the author of 16 textbooks on clinical trial methods and the processes of drug discovery and development, which are widely considered to be the standard references on clinical trials and drug development.
Special Advisor to the Chairman
Tommy G. Thompson
Since February 2005, Secretary Thompson has been a partner in Akin Gump Strauss Hauer & Feld LLP, a law firm. From February 2001 to January 2005, Secretary Thompson served as Secretary of the Department of Health and Human Services under President George W. Bush. From 1987 to February 2001, Secretary Thompson served as Governor of the State of Wisconsin. Secretary Thompson has received numerous public service awards, including The Anti-Defamation League's Distinguished Public Service Award, Governing Magazine's Public Official of the Year Award, and the Horatio Alger Award. The Secretary has served as chairman of the National Governors' Association, the Education Commission of the States and the Midwestern Governors' Conference. Mr. Thompson serves as a member of the board of directors of C.R. Bard, Inc., a surgical and medical instruments company, and Centene Corporation, a managed care organization. Secretary Thompson is a graduate of, and received his law degree from, The University of Wisconsin-Madison.
New Penny order - N.P.O. KNOS. MOMO $0.0007:
http://investorshub.advfn.com/boards/board.aspx?board_id=21116
Hey, friends. This time around our MOMO is coming a bit differently. This stock has been on our watch/radar for some time and is set for a nice surge on Monday. There are many people realizing the breakout potential and getting on board this fast moving train. I am looking for a break into the mid .001s at least on Monday, with the possibility of testing .002. See the weekly candlesticks to see the potential contained here with a volume surge.
KNOS -- Kronos Advanced Technologies - .0007 - Strictly MOMO - Trade to trade well.
PENNY WATCH. Weekly Contest:
http://investorshub.advfn.com/boards/board.aspx?board_id=20776
CURRENT PENNYWATCH PENNY CONTEST ENTRIES ,TO ENTER THE CONTEST PLEASE : Visit and Boardmark the board
http://investorshub.advfn.com/boards/board.aspx?board_id=20776
WEEKLY STOCK PICKS CONTEST 11-6-11
CONTESTANT NAME TICKER STOCK PRICE END STOCK
etown1 BZCN .0001
TraderForLife009 CHWM .004
JJL EEDG .016
livetowatch EMBA .045
Salmonchaser ENKG .0009
uponstocksme HPGS .077
pennybuster ITNS .075
wolverine02 MDGC .0008
ErnieBilco PURO .0001
Hashu SEGI .0134
akstmm TSNP .0001
jedijazz NXOI .0106
STOCKGOODIES PLAYS OF THE WEEK. CURX. Comprehensive Post:
http://investorshub.advfn.com/boards/board.aspx?board_id=18582
CURAXIS Pharmaceuticals - CURX
IHUB DD Post- http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68712355
About Us
Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Our initial focus is Alzheimer's Disease (or AD).
Our lead product is a patented treatment that has shown the potential for treating and halting the progression of this devastating disease. Today, over 5,300,000 Americans suffer with Alzheimer's Disease.
It is estimated that more than $100 billion is spent annually in the United States to treat and care for those with this ailment. Sadly, these numbers are growing every day as the situation for many patients and their families grows desperate, despite the millions of dollars spent annually to find the answer to effectively treating this disease.
Curaxis Pharmaceutical is moving to guide our patented treatment through the necessary clinical trials in order to make it available for patients as quickly as possible. Management believes this product represents a major new development in the battle against Alzheimer's Disease. Currently, no medications or treatments halt or materially slows the progression of this disease. Our research results provide a very strong scientific explanation for the age-related onset of the disease, as well as its progressive nature Curaxis' strategy is to initiate enrollment and dose the first patient in a Phase II clinical trial in women with mild to moderate Alzheimer's disease in 2010. This major step for our Company will signify the next stage in the development of Curaxis Pharmaceutical and a major milestone towards commercialization of our premier product to treat Alzheimer's Disease.
The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011. Please click here to download the proxy materials and to vote.
https://www.iproxydirect.com/index.php/CURX
Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focu s is Alzheimer's Disease (or AD). The lead product is a patented treatment, Memryte, that has shown the potential for treating and halting the progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer's Association, "Changing the Trajectory of Alzheimer's Disease: A National Imperative" shows that in the absence of disease-modifying treatments, the cumulative cost of care for people with Alzheimer's from 2010 to 2050 will exceed $20 trillion in today's dollars.
The new report is not all bad news, however, as it shows that Medicare and Medicaid can achieve dramatic savings - and lives could be significantly improved - with even incremental treatment improvements.
Harry John's, President & CEO of the Alzheimer's Association said, " Today, there are NO treatments that can prevent, delay, slow or stop the progression of Alzheimer's disease. While the ultimate goal is a treatment that can completely prevent or cure Alzheimer's, we can see that even modest improvements can have a huge impact."
Market Need - Curaxis Solution
Currently marketed Alzheimer's drugs target the symptoms of Alzheimer's disease by enhancing some patients' cognitive function and general behavior, but generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors - current theory) experience a modest improvement in cognitive function. According to the Alzheimer's Association, for those patients who show improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes that Memryte may substantially slow the progression of Alzheimer's disease and represent a significant clinical improvement over current drugs.
Corporate Office
Curaxis Pharmaceutical Corp.
1004 Chagford Way
Raleigh NC 27614
United States
Curaxis' Theory
Curaxis' scientific theory is novel yet consistent with current theories of Alzheimer's Disease (AD) and the major hypotheses regarding the cause(s) of Alzheimer's disease.
Alzheimer's disease (AD) is a neurodegenerative disease that ultimately leads to death in afflicted individuals. Previous estimates suggest that there are 4.5 million people with AD in the U.S. alone, many of whom remain undiagnosed. A consensus report published in The Lancet in December of 2005 (1) stated new statistics about the current prevalence of AD and how it will increase in the future. This report estimates that the number of AD patients will double every 20 years to 42.3 million cases by the year 2020 and to 81.1 million cases by the year 2040. A more conservative estimate of AD prevalence published in Alzheimer's and Dementia in 2005 (2) predicted that the annual cost of AD to Medicare and Medicaid alone would exceed a trillion dollars per year by mid-century and AD will consume 4 of every 10 Medicare dollars.
AD research encompasses many therapeutic approaches that hold promise, but no researcher or company has demonstrated to date that they have an approach that will act in a "disease modifying" role, i.e., addressing the root cause of AD. Current Phase III AD trials are few in number and are generally designed only to demonstrate modest decreases in the rate of cognitive decline among AD patients. Several theories exist regarding appropriate biological targets to use in evaluating new therapies for AD. Many therapies under development depend on the theory that \337-amyloid accumulation (diagnostically known as amyloid plaques) is the cause of AD (3) and that removing it will benefit AD patients. Others examine the depletion of estrogen associated with menopause as a trigger for AD in aging women (4), while another theory suggests that sustained or higher testosterone levels may provide benefit to men with AD (5).
Neurofibrillary tangles associated with the phosphorylation of the protein "tau", long time diagnostic hallmarks of AD, are also being investigated (6). Other scientists, including those at Curaxis, believe that dysregulation of the cell cycle in neurons may promote the neuronal cell death that leads to AD and that other AD-associated events result from that dysregulation (7, 8, 9). However, no consensus exists about the cause of AD or how to slow or stop its progression.
AD is a multifaceted disease that has many biochemical and physiological aspects that provide credence to each of the AD-associated theories mentioned above. Since AD is, first and foremost, a disease of aging and is likely multifactorial, it is reasonable to hypothesize that a biochemical change associated with aging might be the trigger for AD. It would also follow that if one identified the major trigger of AD, then it might be able to explain other aspects of AD. Curaxis' scientific evidence to date supports the hypothesis that luteinizing hormone (LH) may be associated with several of the pathological processes that result in AD, and Curaxis' scientific theory is congruent with many mainstream theories regarding how AD arises and how to effectively treat this disease.
Milestones
Curaxis is committed to its mission of delivering a treatment for halting the progression of Alzheimer's Disease. The Company has made significant strides toward that goal. Some of the more recent accomplishments include:
June 2011 - The Company announced changes to its Board of Directors (the "Board") and its executive management team to better position the Company for its next phase of growth and development.The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in the necessary industry arenas to execute the Company's business plan on an accelerated basis.
July 2010 - The Company announced completion of its reverse merger (the "Merger") with Auto Search Cars, Inc. ("Auto Search"). As a result of the Merger, the company will concentrate exclusively on clinical development of Curaxis' drug pipeline.
October 2009 - Curaxis adds to the management team and board in order to guide the Company through all required development processes. Resources include internal and external experts in basic scientific research, drug development, manufacturing, clinical research and regulatory affairs.
2007 - Curaxis discovers genetic-specific differences in male and female AD brains relevant to treatment methodology.
2007 - Curaxis demonstrates that high doses of Memryte stop or slow tumor growth in numerous cancer cell lines.
2006-2007 - Curaxis demonstrates that Memrye stops tau phosphorylation and oxidative stress.
2006 - Curaxis discovers autocrine-paracrine signaling in neurons and many cancers. Management files applicable patents.
2005 - Working with Durect Corporation, Curaxis initiates first use of its proprietary implant with a unique delivery profile for use in treating Alzheimer's disease.
2004 - Curaxis files for patents using Memryte and acetcholine inhibitors and NMDA receptor agononists.
2004 - Curaxis initiates an open label extension study for women who complete the one-year, double blind, placebo controlled Phase II trial.
2004 -Our Research Labs in Research Triangle Park commence studies in order to focus on further exploring Curaxis' basic scientific hypothesis in a number of specific therapeutic targets.
2004 - Curaxis demonstrates that Memryte stops cell cycling-division and apoptosis.
2003 - Curaxis successfully initiates a one-year, double blind, placebo controlled Phase II clinical trial in men, designed to further demonstrate the efficacy and safety of a patented product in the treatment of Alzheimer's Disease.
2003 - Curaxis successfully initiates our double blind, placebo controlled, one year Phase II clinical trial in women to demonstrate the efficacy and safety of a patented product in the treatment of Alzheimer's Disease
The Company continues to build relationships and collaborate on additional research with a network of leading Alzheimer's researchers across the United States and in Australia. These efforts continue to generate important new data that supports our hypothesis and offers a strong scientific case for use of Curaxis' patented treatment.
Curaxis' research findings have been published in a number of respected, peer-reviewed journals. Most recently, we reported in the The Journal of Biological Chemistry, a link between the marked increases i n serum LH following menopause/andropause and A\337 secretion and deposition in the aging brain.
Working with DURECT Corporation, a leading drug development company, Curaxis has completed initial development of a unique dose and delivery formulation for a patented Alzheimer's treatment.
In collaboration with recognized epidemiologists, Company researchers supported an epidemiological study that offers compelling data and findings, that further support the hypothesis and provides additional evidence of the potential efficacy of Curaxis' proposed Alzheimer's treatment.
**All research and development of the Company prior to 2009 was carried out under the name Voyager Pharmaceutical Corp. Historical references and literature concerning Voyager Pharmaceutical, its research, developments and operations represent the legacy development of Curaxis Pharmaceutical.
Pipeline
Our therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis.
This platform is built on the premise that hormones associated with this axis are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers.
We believe our discovery of a duplicate HPG axis at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer's disease as well as many cancers.
Our Alzheimer's Disease Program
Leuprolide acetate, a peptide hormone, has been widely used over the past twenty years for the treatment of a number of hormone-related disorders, most notably prostate cancer and endometriosis and precocious puberty, and has a well-established safety profile. Voyager has conducted extensive preclinical and clinical studies exploring the use of leuprolide acetate for the treatment of Alzheimer's disease in mild-to-moderate patients.
The results to date are very encouraging and point especially to a potentially significant new treatment for women with Alzheimer's disease.
Women represent approximately two-thirds of Alzheimer's patients.
Men present greater challenges in the use of leuprolide to treat Alzheimer's disease because leuprolide suppresses their production of testosterone, which could necessitate patient self-administration of supplemental testosterone and which can lead to wide swings in testosterone blood serum levels.
Therefore, in the near-term, we plan to concentrate our development efforts on the use of leuprolide acetate to treat women, although we will continue our efforts to better understand mechanisms that might lead to optimum outcomes in men.
Our Oncology Program
We have conducted an extensive preclinical research program in the use of leuprolide acetate to treat a number of cancers, including hor mone refractory prostate cancer, brain cancers, kidney cancer, pancreatic cancer and non-small-cell lung cancer.
Our work in oncology is based on new insights into the growth of cancer cells that have been discovered by our scientists. In particular, our scientific findings relating to autocrine-paracrine signaling and the replication of the hypothalamic-pituitary-gonadal axis (the HPG axis) inside of cancer cells point to a previously unknown mechanism that drives the growth of cancer cells and an entirely new method of attacking those cancer cells; i.e., using high doses of leuprolide acetate to eliminate the gonadotropins that may be driving the growth of those cells.
Our preclinical testing of this new treatment approach has produced extremely encouraging results. In both in vitro and in vivo experiments, we have demonstrated a potentially important new therapy for the treatment of a number of cancers.
We plan to use the same compound for our various cancer Phase II clinical trials as we are using for clinical trials of VP4896. Since we have completed Phase I safety trials of VP4896, we believe that we will be able to commence our clinical programs for various cancers with Phase II clinical trials instead of Phase I safety trials. However, the FDA will have to agree to the commencement of these clinical programs with Phase II clinical trials when we submit our Investigational New Drug Applications, or INDs, to the FDA.
Disease Indication Development Status
Hormone refractory prostate cancer Ready for initiation of proof of concept clinical trials
Adult brain cancers (Glioblastoma, stage III, IV) Ready for initiation of proof of concept clinical trials
Renal cell carcinoma Ready for initiation of proof of concept clinical trials
Pancreatic cancer Ready for initiation of proof of concept clinical trials
Non-small cell lung cancer Preclinical testing to continue
History
Curaxis' history dates to an insight from the mid-1990's concerning how changes in various hormone levels impact our health as we age. Most everyone knows that, as we age, our hormone levels change. In particular, it is well known that as we age, levels of estrogen decline precipitously in women, leading to menopause, and levels of testosterone gradually decline in men, leading to andropause. However, while a great deal of research has previously been devoted to the effects of declining estrogen and testosterone on our health, including our mental abilities, Curaxis has taken this research in a broader direction.
Specifically, Curaxis was founded in 2001 (as Voyager Pharmaceutical Corp.) to take a step back from a singular focus on estrogen and testosterone to examine the entire HPG axis, which regulates production of estrogen and testosterone throughout our lives. Curaxis' initial hypothesis was that changes in the levels of hormones in this axis other than estrogen and testosterone play a key role in various diseases of aging. During 2001 and the years that immediately followed, Curaxis devoted substantial research to testing this hypothesis. Also during 2001, Curaxis was awarded a broad patent covering its unique approach to the treatment of Alzheimer's.
As a result of Curaxis' research, it became increasingly clear that one hormone of the HPG axis, called luteinizing hormone or LH, may play a central role in the pathologies that lead to Alzheimer's as well as other diseases of aging, including many cancers. Levels of LH increase dramatically as women enter menopause and increase substantially in men as they age and testosterone production declines. In numerous preclinical studies, Curaxis' research showed that these increased levels of LH were likely a key contributor to developing Alzheimer's.
Developing A Focus
Having determined that high levels of LH represented a potential cause of Alzheimer's, Curaxis then focused on using leuprolide acetate, which eliminates or dramatically reduces LH levels, as a treatment for Alzheimer's. Curaxis' focus on LH followed two parallel paths.
First, in 2002, Curaxis entered into an agreement with Durect Corporation to develop a proprietary implant that would release leuprolide acetate at targeted levels over a two month dosing period. Work on development of this implant commenced in 2002 and culminated in 2005 with a successful Phase 1 trial of the safety and tolerability of the implant.
Second, because leuprolide acetate had been used for many years to treat other diseases, including prostate cancer, in early 2003 Curaxis commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer's in women, using a commercially available dose of leuprolide. In addition, in late 2003 Curaxis commenced a Phase 2 clinical trial to treat mild-to-moderate Alzheimer's in men, again using a commercially available dose of leuprolide.
This parallel path enabled Curaxis to significantly shorten development for its Alzheimer's candidate. As a result, by mid-2005, Curaxis had successfully completed dosing in the Phase 1 trial of its proprietary implant developed with Durect, which Curaxis calls Memryte, and had also completed its Phase 2 trial of leuprolide in women. The results of both of these trials were encouraging and Curaxis began making plans for Phase 3 trials of Memryte. Based on FDA filings and a meeting with the FDA in August 2005, Curaxis launched its Phase 3 trials of Memryte in September 2005.
Also in September 2005, Curaxis (then Voyager Pharmaceutical) filed for its initial public offering, in order to raise sufficient funds for its Phase 3 trials. Based on the strength of its preclinical and clinical data and its management, it was anticipated that a successful IPO would follow later in 2005. Unfortunately, a leading contributor to the research and a significant shareholder of the company took medical leave at the height of these efforts. Complications associated with his illness and absence forced the company to withdraw from the IPO process.
Initial Results
The results of the Phase 2 clinical trial in men were obtained in mid-2005. However, although there were positive signals in those results, the results were confounded by the need to provide supplemental testosterone to men on active treatment in the trial.
During 2006, Curaxis renewed its efforts to obtain private capital to complete its Phase 3 trials. Although it enjoyed some success, it was unable to obtain the full amount needed and was forced to terminate the Phase 3 trials in late 2006. During the remainder of 2006 and 2007, Curaxis worked to obtain the maximum amount of data from these terminated trials. Although the data was incomplete due to the early termination of the trials, the date obtained provided further support for the use of leuprolide to treat mild-to-moderate Alzheimer's, particularly in women.
During 2008 and 2009, Curaxis has regrouped in its efforts to move forward with Memryte. Although Curaxis was unable to make progress in the clinical development of Memryte during this period, the field of Alzheimer's research was not static during this period. A number of Phase 3 Alzheimer's trials, which focused on a target called beta amyloid to treat Alzheimer's, failed to meet their endpoints during 2007-2009. Curaxis has long believed that a focus solely on beta amyloid as a target to treat Alzheimer's is incorrect and the failures of these trials support that view. Most importantly, Curaxis believes that the failure of these trials will broaden acceptance of other approaches to treating Alzheimer's, including Curaxis' approach.
In 2009, Curaxis entered into a series of agreements with Southridge Business Solutions Group ("Southridge") in order to restructure its balance sheet and establish a trading market for its common stock. Under the terms of those agreements, Southridge assisted Curaxis in negotiating settlements with its creditors to eliminate or substantially reduce and defer its trade debt. To date, Curaxis has realized reductions in excess of $6 million in liabilities as the result of the combined efforts. In addition, Southridge assisted Curaxis in securing a $25 million equity facility under which the Company can periodically, over a period of three years, sell up to $25 million of its common stock to an affiliate of Southridge. On December 8, 2010, the Company filed a Registration Statement on Form S-1 to register 13,000,000 shares of common stock to be reserved for issuance under the Equity Line Facility.The proceeds of the equity facility will be used, in part, to fund the next steps in the Company's clinical development plan.
In July, 2010, Curaixs completed a reverse merger into a public shell Corporation. As a result, the Company's common stock is now traded on the OTC Quote Board under the symbol "CURX." In addition, Curaxis began trading on the Frankfurt Stock Exchange under the ticker "8CX" on February 7, 2011.
On June 27, 2011, the Company announced changes to its Board of Directors (the "Board") and its executive management team to better position the Company for its next phase of growth and development. The new Board has a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in all of the necessary industry arenas to execute the Company's business plan on an accelerated basis.
Going Forward
The Board is in the process of completing a comprehensive analysis of the financial position of the Company and is evaluating potential funding alternatives. In addition, the Board has been focused on several remaining transition items including, but not limited to, the efficient processing of capital transactions for pre-merger shareholders, the scientific evaluation of the Company's inventory of pre-clinical and clinical data and related intellectual property and, the development of strategic alternatives.
DOWNLOAD: Alzheimers Research Report (PDF)
http://www.curaxispharma.com/images/pdf/alzheimers_research_report.pdf
BLOGS http://blog.curaxispharma.com/
CURX Partners
Curaxis has engaged a very impressive infrastructure of scientific/technical, medical and legal advisers as strategic partners. This allows the Company to leverage talented individuals who provide key knowledge, expertise and support. A selection of these partnerships is represented by:
Our collaboration in discovery research with leading Alzheimer's research teams led by George Perry, PhD, Mark A. Smith, PhD http://www.cwru.edu/med/pathology
Leading patent and FDA legal support from Covington & Burling http://www.cov.com
Clinical and FDA regulatory support from Bert Spilker & Associates (http://www.bertspilker.com);
Drug development and delivery support from DURECT Corporation (http://www.durect.com);
Website and marketing communications support by Sage Communications, LLC. (http://www.cwru.edu/med/pathology)
Case Western Reserve University - Department of Pathology
World-class research is conducted in the Department of Pathology with major emphasis on the following areas and more: cancer biology, infection and immunity, neurobiology/neuropathology, tissue injury and healing, and biomaterials biocompatibility. These emphasis areas are reflected in the three tracks of the Pathology Graduate Program: the Cancer Biology Training Program (CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program provides extensive opportunities for PhD or MD-PhD training in these areas. A separate program leads to the MS degree.
Covington & Burling LLP
Covington & Burling LLP represents clients in cutting-edge technology, litigation, white collar defense, transactional, governmental affairs, international, life sciences and other matters. In responding to the needs and challenges of our clients, our lawyers draw upon the firm's expertise and experience in a broad array of industries to provide solutions to difficult, complex, and novel problems and issues, whether in litigation, transactions, or regulatory proceedings.
Bert Spilker & Associates
The mission of Bert Spilker & Associates (BS&A) is to provide clients with the highest quality, most cost-effective, and timely pharmaceutical consulting services available. To achieve this goal, Bert has assembled a group of over 150 independent associates who are available to assist him in most aspects of drug discovery, drug development and strategy setting. BS&A strives to build long-term relationships with clients based on knowledge of his clients culture, research, products and services.
Sage Communications Advertising and Public Relations
Sage Communications is a full-service, integrated marketing firm that provides advertising, public relations, and strategic marketing services to clients from across the street to across the globe, from emerging start-ups, to major Fortune 500 companies. Throughout our history, our mission has remained the same: Align marketing strategy to directly impact our clients' bottom line. We are located in Tysons Corner, VA
CURX Security Details
Curaxis Pharmaceutical Corporation is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "CURX", and within the OTCQB market tier. As such, Business, operational and financial information on CURX is fully transparent and available to public view.
Visit http://www.otcmarkets.com/stock/CURX/quote for more information.
Market Value1 $5,357,650 a/o Nov 03, 2011
Shares Outstanding 76,537,861 a/o Aug 11, 2011
Float 16,238,300 a/o Sep 15, 2010
Authorized Shares 480,000,000 a/o Aug. 12 2011
Par Value 0.0001
(per otcmarkets)
Per FORM 10Q link listed below
As of August 11 , 2011, there were 76,537,861 shares outstanding of the registrant's common stock.
Common stock, $0.0001 par value; 480,000 authorized; 72,216 and 76,474 shares issued and outstanding at December 31, 2010 and June 30, 2011, respectively.
Transfer Agent
Direct Transfer, LLC.
500 Perimeter Park Drive Suite D
Suite D
Morrisville, NC, 27560
919-481-4000
http://www.issuerdirect.com
ta@issuerdirect.com">http://ta@issuerdirect.com
10Q reported Aug 12, 2011 period ending Jun 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8096721
Shareholders of Record: 41 a/o Apr 15, 2010
SIC - Industry Classification: 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc.: 2008 and On July 30, 2010, the Company entered into an agreement and plan of merger with Curaxis Pharmaceutical Corporation, a Nevada corporation formed solely for the purpose of a name change. Pursuant to the Short-Form Merger, the Company changed its name to Curaxis Pharmaceutical Corporation ("Curaxis" or the "Company")
In February 2011, the Company was granted approval and listed its stock to trade on the Frankfurt stock exchange ("FSE") under the symbol 8CX to expand its global capital markets access.
Security Notes
Capital Change=shs increased by 91 for 1 split. Ex-date=01/12/2010. Rec date=12/09/2009. Pay date=01/11/2010
Company Notes
Formerly=Auto Search Cars, Inc. until 9-2010
Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com
CURX Recent News
RED HOTT
The 2011 Curaxis Pharmaceuticals Corp Annual Meeting of shareholders will be held on November 8th 2011.
Quote: Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focu s is Alzheimer's Disease (or AD). The lead product is a patented treatment, Memryte, that has shown the potential for treating and halting the progression of this devastating disease.
The Problem
Washington DC, May 19, 2010, A new report from the Alzheimer's Association, "Changing the Trajectory of Alzheimer's Disease: A National Imperative" shows that in the absence of disease-modifying treatments, the cumulative cost of care for people with Alzheimer's from 2010 to 2050 will exceed $20 trillion in today's dollars.
The new report is not all bad news, however, as it shows that Medicare and Medicaid can achieve dramatic savings - and lives could be significantly improved - with even incremental treatment improvements.
Harry John's, President & CEO of the Alzheimer's Association said, " Today, there are NO treatments that can prevent, delay, slow or stop the progression of Alzheimer's disease. While the ultimate goal is a treatment that can completely prevent or cure Alzheimer's, we can see that even modest improvements can have a huge impact."
Market Need - Curaxis Solution
Currently marketed Alzheimer's drugs target the symptoms of Alzheimer's disease by enhancing some patients' cognitive function and general behavior, but generally are not thought to slow progression of the disease.
Only about 50% of patients taking AChEIs (acetylcholinesterase inhibitors - current theory) experience a modest improvement in cognitive function. According to the Alzheimer's Association, for those patients who show improvement, the benefit typically lasts for only six months to one year.
Based on preclinical and clinical results achieved to date, Curaxis believes that Memryte may substantially slow the progression of Alzheimer's disease and represent a significant clinical improvement over current drugs.
Aug 17, 2011 Curaxis Pharmaceutical Corporation Management Working Through Transition Phase and Evaluating Alternatives
Jun 27, 2011 Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
May 10, 2011 Curaxis Pharmaceutical Corporation Chief Executive Officer Comments on Recent NIH Research
May 5, 2011 Curaxis' Memryte Named One of the Top 100 Drugs in Development Today by R&D Directions
Mar 24, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana Research
Mar 10, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent New York Times Article "Drug Firms Face Billions in Losses in '11 as Patents End"
Feb 14, 2011 Curaxis Pharmaceutical Corp. to Meet With Ticino Business Development Office in Lugano, Switzerland
Feb 9, 2011 Curaxis Pharmaceutical Corp. Announces New Listing on the Frankfurt Stock Exchange
Feb 7, 2011 Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Alzheimer's Association Report
Feb 3, 2011 Curaxis Pharmaceutical Management on Roadshow in Europe to Access Capital & Pursue Strategic Partners
CURX Core Management Team
Timothy R. Wright - Chairman and Interim Chief Executive Officer
A seasoned executive with over 25 years of life sciences experience, Timothy Wright has comprehensive operating and strategic management experience, which encompasses pharmaceuticals, medical device, diagnostics and pharmaceutical services. Prior to joining Curaxis as Chairman of the Board and interim Chief Executive Officer, Mr. Wright was a Senior Vice President and President of the pharmaceuticals division at Covidien (Mallinckrodt). He previously served as President of Global Operations at Elan BioPharmaceuticals and spent 17 years at DuPont Merck Pharmaceuticals, where he was classically trained in the pharmaceutical industry. He brings significant global operating and product launch experience and has served on the boards of four public and four private global life sciences companies.
Judith S. T. Geaslen - VP Finance
Judith S. T. Geaslen has been the Company's Vice President of Finance and Chief Accounting Officer since August 2009 after serving as Corporate Controller and Accountant since July 2004. From March 1999 to April, 2000, Ms. Geaslen served as Vice President and Corporate Controller at Wilmington Trust Corporation, a financial holding company engaged in providing a range of banking and other financial services through its banking and other subsidiaries, and from 1994 to 1999, served as Vice President and Manager of the Asset Review Division. From September 1984 to September 1994, Ms. Geaslen was employed by Ernst & Young, a registered public accounting firm, mostly recently serving as Audit Senior Manager. Ms. Geaslen is a graduate of Saint Mary's College, Notre Dame, Indiana.
CURX Contact Info
Curaxis Pharmaceutical Corp
1004 Chagford Way
Raleigh, NC 27614
Website: http://www.curaxispharma.com
Phone: 888-919-2873
Email: jgeaslen@curaxispharma.com
twitter: http://twitter.com/#!/curaxispharma
facebook: http://www.facebook.com/pages/Curaxis-Pharmaceutical-Corporation/159104304105704
Plano. I'll go look again.
I am on a new board STOCK BADDIES. Come by and say hi.
http://investorshub.advfn.com/boards/board.aspx?board_id=22617
STTN reports put out last week and i missed them...going to buy them
Pro Traders Forum. TRAB.
http://investorshub.advfn.com/boards/board.aspx?board_id=18631
Well I hope no one gave this one up on the dips if they bought
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68719645
sc
Volume_Alerts 10Day_Moving_Avg + iHubfresh Watch_List [2]:
http://investorshub.advfn.com/boards/board.aspx?board_id=21832
..................................................................
Add this one too your watch list:
MDEX .015 Madison Explorations Inc ihubfresh It is being accumulated http://ih.advfn.com/p.php?pid=historical&cb=1264248899&symbol=mdex even though it's dropped a few points.
If you scan back 'historical' you see it from from .003 to .022 in one-day but not reported here on iHub. http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=%20mdex
Scanning further 'historical' and once you get pasted the .0054's 'zero', another good indicator too WATCH.
Madison Explorations Inc
http://www.madisonexploration.com/
>From Oct 28th 'zero' A/D 1_month too 147k now
sc
.................................................................
CGCO.01 ihub fresh http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=%20cgco
interesting post in March http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61444840&txt2find=cgco
http://www.commercegroupcorp.com/index.html under construction Last updated Oct 17th 2011
http://www.commercegroupcorp.com/news.html
http://www.sec.gov/Archives/edgar/data/109757/000010975711000007/0000109757-11-000007-index.htm
Shares Outstanding 30,750,869 a/o Feb 18, 2011
Float 19,500,000 a/o Mar 31, 2010
On-Watch a few weeks
sc
..................................................................
I will go look. Thanks.
Poem..lotto tsnp worth 5 bags easy!
PRO TRADERS STOCK FORUM. LBYE. YTBLA. NLEF:
http://investorshub.advfn.com/boards/board.aspx?board_id=18631
LBYE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68707173
YTBLA: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68707642
NLEF: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68706719
DYR DoYourResearch
Quite a few very nice gainers in the last few weeks...
sc
uponstocks4me. Thanks for coming by.
Come by "A Dawgg" some time:
http://investorshub.advfn.com/boards/board.aspx?board_id=21519
HPGS lots of upside on this one
PRO TRADERS FORUM. HPGS:
http://investorshub.advfn.com/boards/board.aspx?board_id=18631
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68619918
News Friday,
announced Mark Hettinger and Joe Hettinger, both of whom are company founders and directors, have converted debt owed to them by High Plains Gas, Inc. into shares of common stock. The transactions are expected to save the company approximately $500,000 per year in interest payments and reduce its outstanding debt by nearly $6 million.
Brandon Hargett, CEO of High Plains Gas, commented, "As CEO, I understand what great sacrifices the Hettingers have made in bringing our company from a 92-well methane producer to a public entity with over 1,600 wells and a sizeable and rapidly growing construction subsidiary. Their continued commitment to seeing this company succeed, grow, and prosper is demonstrated by this conversion. It is a pleasure to work with a Board of Directors that demonstrates this level of belief in what we are building."
HPGS has had an excellent run from .07 to .084 HOD on Thursday closing at .08
The A/D went from a positive 1.48mil Thurs. too a positive 2.05mil close of business on Friday.
This looks too be a really good company in the progress of rebuilding.
http://www.thestreet.com/_yahoo/story/11297126/1/insiders-trading-gnc-cse-hpgs-vprt.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Also on top of latest news they have plenty of cash: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8112954
Current Assets:
Cash and cash equivalents
June 30th 2011 =$1,264,605
Dec 31 2010 = $208,823
As stated above they have CASH, and it's not from dilution, but..... :/
Given the 1st news of two founders converting " converted debt owed to them by High Plains Gas, Inc. into shares of common stock. The transactions are expected to save the company approximately $500,000 per year in interest payments and reduce its outstanding debt by nearly $6 million."
Question is, will they be selling their now common stock on the open market?
Up until Friday I was all over this with a strong possible LTP, Long Term Play.
My thoughts are these... given the REALLY GOODS NEWS sets before Friday too include the latest 10Q.
If the price stays above .075 and moves above .08, and the A/D does not drop below the 1 million mark, it's a strong possibility the founders may sell their stock slowly and quietly into the day of news, high volume and not effect current price.
It's up to each of you too determine during trading hours what part or all of the last paragraph you wish too follow.
As founders they would be stupid too go all this way and then dump into the open market.
If management balances everything out correctly including founders the 52wk LOW of
0349 and even .075 this week should not pop up again. Remember the 52wk high of $1.48 whether it was perceived in what investors called future-value or whatever was accomplished.
Personally for me if it doesn't dip below .072 I'd rather HOLD and see what happens and break even then too get out too early.
HPGS http://www.otcmarkets.com/stock/HPGS/financials
You don't find plays like this too often [at this price range], with this much forward-looking potential! http://www.otcmarkets.com/stock/HPGS/financials
http://finance.yahoo.com/q?s=hpgs&ql=1
sc
STOCKGOODIES PLAYS OF THE WEEK. NewHotBio GoodieMonday Inside:
http://investorshub.advfn.com/boards/board.aspx?board_id=18582
We came across this Goodie Kind of Late but We Are Alerting for Monday!
Its a Hot Bio Stock Listing on the OTCBB Exchange
Watch Your Emails Over the Weekend for More Info and Due Diligence!
Mondays New StockGoodie is CURAXIS Pharmaceutical Corp. - $CURX
Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding effective treatments for major age-related diseases. Curaxis' initial focus is Alzheimer's Disease (or AD). The lead product is a patented treatment that has shown the potential for treating and halting the progression of this devastating disease.
Today, over 5,300,000 Americans suffer with Alzheimer's Disease. It is estimated that more than $100 billion is spent annually in the United States to treat and care for those with this ailment. Sadly, these numbers are growing every day as the situation for many patients and their families grows desperate, despite the millions of dollars spent annually to find the answer to effectively treating this disease.
Curaxis Pharmaceutical is moving to guide our patented treatment through the necessary clinical trials in order to make it available for patients as quickly as possible. Management believes this product represents a major new development in the battle against Alzheimer's Disease. Currently, no medications or treatments halt or materially slow the progression of this disease. Our research results provide a very strong scientific explanation for the age-related onset of the disease, as well as its progressive nature.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
593
|
Created
|
09/28/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |